View in EDS

Fasting conditions in clinical oncology trials and drug labelling - Authors' reply.

Saved in:
Bibliographic Details
Title: Fasting conditions in clinical oncology trials and drug labelling - Authors' reply.
Authors: Lubberman FJE; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands. Electronic address: floor.lubberman@radboudumc.nl., Burger D; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands., van Erp NP; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2017 Sep; Vol. 18 (9), pp. e507.
Publication Type: Letter; Comment
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28884695
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Fasting conditions in clinical oncology trials and drug labelling - Authors' reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lubberman+FJE%22">Lubberman FJE</searchLink>; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands. Electronic address: floor.lubberman@radboudumc.nl.<br /><searchLink fieldCode="AU" term="%22Burger+D%22">Burger D</searchLink>; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Erp+NP%22">van Erp NP</searchLink>; Department of Pharmacy, Radboud University Medical Center, Nijmegen 6500 HB, Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2017 Sep; Vol. 18 (9), pp. e507.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter; Comment
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28884695
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(17)30599-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e507
    Titles:
      – TitleFull: Fasting conditions in clinical oncology trials and drug labelling - Authors' reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lubberman FJE
      – PersonEntity:
          Name:
            NameFull: Burger D
      – PersonEntity:
          Name:
            NameFull: van Erp NP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2017 Sep
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1